EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Pfizer stock inched down Tuesday on a mixed first-quarter report. Sales missed, but cost cutting led to strong earnings.

Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...